Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
In adult hypophosphatasia, low tissue-nonspecific alkaline phosphatase activity allows inorganic pyrophosphate to build up, and that excess PPi both blocks normal mineralization and crystallizes as calcium pyrophosphate dihydrate in tendons, ligaments, and entheses, producing calcific periarthritis, pseudogout flares, chondrocalcinosis, and painful enthesopathy that is often mistaken for tendinitis or seronegative spondyloarthritis. Management is usually multimodal: NSAIDs or colchicine for acute crystal attacks, targeted corticosteroid injections, physical therapy and load modification for enthesopathy, correction of vitamin D insufficiency without high-dose supplementation, and careful avoidance of bisphosphonates and other antiresorptives, which can worsen mineralization defects and fracture healing. Enzyme replacement with asfotase alfa, anabolic options, and specialist metabolic bone referral are considered in selected adults with severe, refractory disease. There are several important nuances in dosing, drug avoidance, and differential diagnosis to consider, so see below to understand more before deciding on next steps.
Because enthesial pain, recurrent flares, and stress fractures can look like many other conditions, it helps to organize your symptoms before your next appointment. A free, instant, online symptom check can help you clarify what you are experiencing, flag patterns
Adult hypophosphatasia (HPP) is a rare inherited disorder caused by deficient activity of tissue-nonspecific alkaline phosphatase (TNSALP). One hallmark of HPP in adults is enthesopathy tendon calcification: painful calcium deposits at tendon and ligament attachments (entheses). Understanding why this happens—and how to manage it—can help you find relief and protect your mobility.
In HPP, low alkaline phosphatase levels lead to an imbalance in minerals around bones and soft tissues. Key drivers of tendon attachment calcification include:
Accumulation of inorganic pyrophosphate (PPi)
• TNSALP normally breaks down PPi, a natural inhibitor of mineralization.
• When TNSALP is low, PPi builds up and combines with calcium, forming crystal deposits at entheses.
Local mechanical stress
• Tendon attachments are under constant tension.
• Microtrauma from walking, running or repetitive motion encourages calcium crystal precipitation.
Chronic inflammation
• Deposited crystals trigger an inflammatory response, causing pain, swelling and further tissue damage.
Over time, these factors create noticeable, painful bumps or hard nodules where tendons attach to bone (for example, the back of the heel or outside of the elbow).
Enthesopathy tendon calcification in adult HPP often presents as:
Common sites include the Achilles tendon (heel), plantar fascia (sole), lateral epicondyle (elbow) and patellar tendon (knee).
A thorough evaluation helps distinguish HPP-related enthesopathy from other causes (e.g., arthritis or overuse):
Laboratory studies
Imaging
Genetic testing
While there’s no cure other than targeted enzyme replacement, a multifaceted approach can ease pain and improve function.
• Asfotase alfa is a recombinant TNSALP approved for pediatric and adult HPP.
• It reduces PPi levels, slowing or reversing calcification over months.
• Regular injections are required; discuss with an endocrinologist or metabolic bone specialist.
Use these medications at the lowest effective dose and under medical supervision.
A physical therapist experienced in metabolic bone disorders can tailor a program to your needs.
Discuss benefits and risks of each procedure with your physician.
These measures protect the tendon attachments and prevent new calcifications.
Always check labs before starting supplements, as adults with HPP can develop hypercalcemia.
Ask your specialist about clinical trials for novel treatments in adult HPP.
If you’re unsure whether your symptoms match HPP-related enthesopathy, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Although enthesopathy tendon calcification is rarely life threatening, severe inflammation or unexpected weakness warrants prompt evaluation. Speak to a doctor if you experience:
For any life-threatening or serious concern, always seek emergency care or contact your healthcare provider right away.
Managing tendon attachment calcification in adult HPP involves targeted therapies, lifestyle adjustments and regular medical follow-up. By combining enzyme replacement, symptom relief, physical therapy and wise activity choices, you can reduce pain and preserve mobility. Above all, partner with your healthcare team—endocrinologists, rheumatologists, physical therapists—to create a personalized plan. And remember: when in doubt, speak to a doctor about any new or worsening symptoms.
(References)
* Imai S, Sekigawa S, Yamamoto H, Okuyama T, Tsubura Y. Hypophosphatasia. Acta Pathol Jpn. 1982 Sep;32(5):901-5. doi: 10.1111/j.1440-1827.1982.tb03204.x. PMID: 7136701.
* Mornet E. Hypophosphatasia. Orphanet J Rare Dis. 2007 Oct 4;2:40. doi: 10.1186/1750-1172-2-40. Epub 2007 Oct 4. PMID: 17916236; PMCID: PMC2164941.
* Beck C, Morbach H, Stenzel M, Schneider P, Collmann H, Girschick G, Girschick HJ. [Hypophosphatasia]. Klin Padiatr. 2009 Jul-Aug;221(4):219-26. doi: 10.1055/s-0029-1220718. Epub 2009 Jul 23. PMID: 19629901.
* Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016 Apr;12(4):233-46. doi: 10.1038/nrendo.2016.14. Epub 2016 Feb 19. PMID: 26893260.
* Kishnani PS, Rockman-Greenberg C, Rauch F, Bhatti MT, Moseley S, Denker AE, Watsky E, Whyte MP. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019 Apr;121:149-162. doi: 10.1016/j.bone.2018.12.011. Epub 2018 Dec 18. PMID: 30576866.
* Simon S, Resch H. Treatment of hypophosphatasia. Wien Med Wochenschr. 2020 Apr;170(5-6):112-115. doi: 10.1007/s10354-020-00736-3. Epub 2020 Feb 18. PMID: 32072352.
* Vimalraj S. Alkaline phosphatase: Structure, expression and its function in bone mineralization. Gene. 2020 Sep 5;754:144855. doi: 10.1016/j.gene.2020.144855. Epub 2020 Jun 6. PMID: 32522695.
* Riancho JA. Diagnostic Approach to Patients with Low Serum Alkaline Phosphatase. Calcif Tissue Int. 2023 Mar;112(3):289-296. doi: 10.1007/s00223-022-01039-y. Epub 2022 Nov 8. PMID: 36348061.
* Reis FS, Lazaretti-Castro M. Hypophosphatasia: from birth to adulthood. Arch Endocrinol Metab. 2023 May 25;67(5):e000626. doi: 10.20945/2359-3997000000626. PMID: 37249457; PMCID: PMC10665056.
* Pascart T, Filippou G, Lioté F, Sirotti S, Jauffret C, Abhishek A. Calcium pyrophosphate deposition disease. Lancet Rheumatol. 2024 Nov;6(11):e791-e804. doi: 10.1016/S2665-9913(24)00122-X. Epub 2024 Jul 29. PMID: 39089298.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.